

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

- 1-14. (cancelled).
15. (currently amended) An isolated antibody that immunospecifically-binds to a an-isolated polypeptide comprising amino acids 1-705 ~~the amino acid sequence~~ of SEQ ID NO: 5, wherein said isolated antibody does not immunospecifically bind to the polypeptide of SEQ ID NO: 52.
16. (original) The antibody of claim 15, wherein said antibody is a monoclonal antibody.
17. (original) The antibody of claim 15, wherein the antibody is a humanized antibody.
- 18-34. (canceled).
35. (currently amended) A composition comprising the antibody of claim 15 and a ~~pharmaceutically acceptable~~ carrier.
- 36-37. (canceled).
38. (previously amended) A kit comprising in one or more containers, the composition of claim 35.
- 39-48. (canceled).
49. (currently amended) An isolated antibody that immunospecifically-binds to a an-isolated polypeptide comprising an amino acid sequence at least 96% identical to the amino acid sequence of amino acids 1-705 of SEQ ID NO: 5, wherein said polypeptide has kinase activity, and wherein said isolated antibody does not bind to the polypeptide of SEQ ID NO: 52.
50. (previously added) The antibody of claim 49, wherein said antibody is a monoclonal antibody.
51. (previously added) The antibody of claim 49, wherein the antibody is a humanized antibody.
52. (currently amended) A composition comprising the antibody of claim 49 and a ~~pharmaceutically acceptable~~ carrier.
53. (previously added) A kit comprising in one or more containers, the composition of claim 52.

54. (currently amended) An isolated antibody that immunospecifically-binds to a ~~an~~-isolated polypeptide comprising an amino acid sequence at least 99% identical to the amino acid sequence of amino acids 1-705 of SEQ ID NO: 5, wherein said polypeptide has kinase activity, and wherein said isolated antibody does not immunospecifically bind to the polypeptide of SEQ ID NO: 52.
55. (previously added) The antibody of claim 54, wherein said antibody is a monoclonal antibody.
56. (previously added) The antibody of claim 54, wherein the antibody is a humanized antibody.
57. (currently amended) A composition comprising the antibody of claim 54 and a ~~pharmaceutically acceptable~~ carrier.
58. (previously added) A kit comprising in one or more containers, the composition of claim 57.
59. (currently amended) An isolated antibody that immunospecifically-binds to a ~~an~~-isolated polypeptide comprising amino acids 28-705 ~~992~~ of SEQ ID NO: 5, and wherein said isolated antibody does not immunospecifically bind to the polypeptide of SEQ ID NO: 52.
60. (previously added) The antibody of claim 59, wherein said antibody is a monoclonal antibody.
61. (previously added) The antibody of claim 59, wherein the antibody is a humanized antibody.
62. (currently amended) A composition comprising the antibody of claim 59 and a ~~pharmaceutically acceptable~~ carrier.
63. (previously added) A kit comprising in one or more containers, the composition of claim 62.
64. (currently amended) An isolated antibody that immunospecifically-binds to a ~~an~~-isolated polypeptide variant of the amino acid sequence of amino acids 1-705 of SEQ ID NO: 5, wherein one amino acid residue in said variant differs from the amino acid sequence of SEQ ID NO: 5, wherein said polypeptide variant has kinase activity, and wherein said isolated antibody does not immunospecifically bind to the polypeptide of SEQ ID NO: 52.

65. (previously added) The antibody of claim 64, wherein said antibody is a monoclonal antibody.
66. (previously added) The antibody of claim 64, wherein the antibody is a humanized antibody.
67. (currently amended) A composition comprising the antibody of claim 64 and a ~~pharmaceutically acceptable~~ carrier.
68. (previously added) A kit comprising in one or more containers, the composition of claim 67.
69. (currently amended) An isolated antibody that immunospecifically-binds to ~~a an isolated~~ polypeptide comprising an amino acid sequence at least 96% identical to the amino acid sequence of amino acids 28-705 ~~the mature form~~ of the amino acid sequence of SEQ ID NO: 5, and wherein said isolated antibody does not immunospecifically bind to the polypeptide of SEQ ID NO: 52.
70. (previously added) The antibody of claim 69, wherein said antibody is a monoclonal antibody.
71. (previously added) The antibody of claim 69, wherein the antibody is a humanized antibody.
72. (currently amended) A composition comprising the antibody of claim 69 and a ~~pharmaceutically acceptable~~ carrier.
73. (previously added) A kit comprising in one or more containers, the composition of claim 72.
74. (newly added) An isolated antibody that immunospecifically-binds to the amino acid sequence of amino acids 726-992 of the amino acid sequence of SEQ ID NO: 5 that does not immunospecifically bind to SEQ ID NO: 52.
75. (newly added) The antibody of claim 74, wherein the antibody is a monoclonal antibody.
76. (newly added) The antibody of claim 74, wherein the antibody is a humanized antibody.
77. (newly added) A composition comprising the antibody of claim 74 and a carrier.
78. (newly added) A kit comprising in one or more containers, the composition of claim 77.
79. (newly added) An isolated antibody that immunospecifically-binds to a polypeptide comprising an amino acid sequence at least 96% identical to the amino acid sequence of

amino acids 726-992 of the amino acid sequence of SEQ ID NO: 5 that does not immunospecifically bind to SEQ ID NO: 52.

80. (newly added) The antibody of claim 79, wherein said antibody is a monoclonal antibody.
81. (newly added) The antibody of claim 79, wherein the antibody is a humanized antibody.
82. (newly added) A composition comprising the antibody of claim 79 and a carrier.
83. (newly added) A kit comprising in one or more containers, the composition of claim 82.
84. (newly added) An isolated antibody that immunospecifically-binds to a polypeptide comprising an amino acid sequence at least 99% identical to the amino acid sequence of amino acids 726-992 of the amino acid sequence of SEQ ID NO: 5 that does not immunospecifically bind to SEQ ID NO: 52.
85. (newly added) The antibody of claim 84, wherein the antibody is a monoclonal antibody.
86. (newly added) The antibody of claim 84, wherein the antibody is a humanized antibody.
87. (newly added) A composition comprising the antibody of claim 84 and a carrier.
88. (newly added) A kit comprising in one or more containers, the composition of claim 87.
89. (newly added) An isolated antibody that immunospecifically-binds to a polypeptide comprising an amino acid sequence at least 99% identical to the amino acid sequence of amino acids 28-705 of the amino acid sequence of SEQ ID NO: 5, and wherein said isolated antibody does not immunospecifically bind to the polypeptide of SEQ ID NO: 52.
90. (newly added) The antibody of claim 89, wherein the antibody is a monoclonal antibody.
91. (newly added) The antibody of claim 89, wherein the antibody is a humanized antibody.
92. (newly added) A composition comprising the antibody of claim 89 and a carrier.
93. (newly added) A kit comprising in one or more containers, the composition of claim 92.
94. (newly added) An isolated antibody that immunospecifically-binds to a polypeptide selected from the group consisting of amino acids 4-11, 20-24, 26-30, 63-67, 85-89, 109-113, 123-127, 170-174, 272-276, 299-303, 304-310, 321-325, 373-377, 391-395, 418-422, 425-429, 596-600, 602-612, 643-647, 653-657, 677-681, 684-688, 733-737, 755-759, 768-773, 782-786, 788-792, 794-798, 843-847, 863-867, 884-890, 894-899, 915-919, and 923-935 of SEQ ID NO: 5, wherein said isolated antibody does not immunospecifically bind to the polypeptide of SEQ ID NO: 52.

- 95. (newly added) The antibody of claim 94, wherein the antibody is a monoclonal antibody.
- 66. (newly added) The antibody of claim 94, wherein the antibody is a humanized antibody.
- 97. (newly added) A composition comprising the antibody of claim 94 and a carrier.
- 98. (newly added) A kit comprising in one or more containers, the composition of claim 97.